On Feb 1st, Mr.Shao Mingli, Deputy Minister of MoH China, General Director of SFDA and Director of 9th Pharmacopoeia Committee had attended the 3rd Committee Congress of Ninth Pharmacopoeia Committee a.k.a. ‘Pharmacopoeia of the PCR’ 2010 Version Editorial Work Summary Meeting, during which, he mentioned ‘All the staff working under the pharmaceutical standard should take the 2010 version of ‘Pharmacopoeia of PCR’ as the new starting point, everyone should take serious consideration on the development direction of the standardization of the national medicines under the new situation, further improve the editing work of the Pharmacopoeia and the standard of national pharmaceutical products, and take a new step towards standardization achievement in the pharmaceutical field of China.’
Mr. Shao emphasized that the elevation of medical standard is a circling and endless developing process. The implementation of new version of the Pharmacopoeia means the start of standard elevation in a new round. From this year, the edition of the Pharmacopoeia (Version 2015) should be put into the work schedule, arranged scientifically and improved actively. The leading principles of the 2015 editorial work and the preparation of R&D plan should be conducted, with the primary researched arranged in advance.
At the meeting, Mr. Shao fully affirmed the work of the ninth Pharmacopoeia Committee: the joint effort made by the 9th Pharmacopoeia Committee and its standing bodies, members of committee in general, the entities which in charge of drafting and reviewing of individual medicine through their thoroughgoing arrangement and day and night working, the edition of Chinese Pharmacopoeia (Version 2010) has been effectively completed, which set a milestone along the history of standard establishment. We should take this successful experience seriously and make the work arrangement of Pharmacopoeia (Version 2015) actively, in order to build a standard medical system with Chinese characteristics, and to offer a greater support for maintaining of the public health.
As regards to the improvement of the national medical standard towards new development, Mr. Shao pointed out: firstly, we should understand the regulations of ‘Medicine Management Regulation’ and ‘The Articles of Laws of Medicine Management Implementation’, take in-depth analysis of the problems existing within the standardization work of national medicine and deep consideration of the authority position of the national Pharmacopoeia Committee and its developing direction. We could be clear about the medical standard system from the source and the responsibility of related entities during work implementation, to provide legal assurance to the systematization and standardization of the medicine. Secondly, by taking the timing of implementing the regulations of national primary medicines as a good opportunity, we should speed up the implementation of ‘the action plan of elevation of national medical standard’. Recently, we should focus on the high risk species, like the varieties, injection solutions, vaccines listed in the national primary medicine catalogue as well as TCM and ethical drug. Thirdly, we should learn from the past experience of editing the Pharmacopoeia, analyze the weaknesses within medical standard management, continuously improve the management system of medicine standard, to strengthen the approval and assessment of the institute which in charge of edition of the Pharmacopoeia and to establish a scientific management system which is effective from the date of implement. Fourthly, we should plan the editorial works of the 2015 version actively. Fifth, we should build up a team with good and compromised talent.
The meeting was hosted by Mr. Wu Zhen, Deputy Director-General of SFDA and Secretary-General of Pharmacopoeia Committee. Mr. Bian Zhenjia, Deputy Director-General of SFDA, Mr. Yu Wenming, Deputy Director-General of SATCM, delegates from MoH, State Ethnic Affairs Commission, Ministry of Science and Technology, Ministry of Health of People's Liberation Army General Logistics Department, etc., had attended the meeting. Upon the agreement of SFDA, the Pharmacopoeia Committee had also given honored Mr. Xiao Peigen and other 20 committee members for their seniority.
Source: Medicine Economic News
Date: 2010-02-03
|